Skip to main content

Vistagen Therapeutics, Inc.

VTGN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001411685

No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Vistagen Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of VTGN: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders56148−7
Shares14.7M58211.8M−2.95M (−20.1%)
Value$8.12M$333$2.54M−$5.58M (−68.7%)

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (9)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to VTGN in Q2 2026
InstitutionSharesValue% of portfolio
Commodore Capital LP2,788,620$630.2K0.04%
Citadel Advisors LLC68,839$15.6K0.00%
Virtu Financial LLC66,021$15.0K0.00%
Confluence Wealth Services, Inc.32,610$7.37K0.00%
Scientech Research LLC30,283$6.84K0.01%
R Squared Ltd27,745$6.27K0.00%
Bank of America Corp16,570$3.75K0.00%
Farther Finance Advisors, LLC15,000$3.39K0.00%
Deutsche Bank AG12,000$2.76K0.00%

Sold out (16)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Not filed for Q2 2026 yet (1)

Institutions that held Vistagen Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding VTGN in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
CWM, LLC582$333